open access

Vol 8, No 4 (2012)
Review paper
Published online: 2012-10-08
Get Citation

The mechanisms of magnesium wasting during the treatment with cetuximab and panitumumab

Anna Buda, Mirosława Puskulluoglu
Onkol. Prak. Klin 2012;8(4):143-150.

open access

Vol 8, No 4 (2012)
REVIEW ARTICLES
Published online: 2012-10-08

Abstract

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor
(EGFR). Their function is to bind specifically to the extracellular domain of EGFR on both neoplastic
and normal cells which blocks the influence of EGF on the receptor. The important side effect of the
treatment with those drugs, apart from skin toxicity, infusion reactions or nausea, is hypomagnesemia.
Studies show that the mechanism responsible for this effect is the inhibition of EGFR by mAbs in distal
convoluted tubule of the nephron. The EGFR blockage through Ras and mitogen-activated protein kinase
suppress transient receptor potential melastatin submember 6 ion channel responsible for magnesium
reabsorption. The inhibition results in magnesium wasting and secondary hypomagnesemia. Almost all
patients treated with mAbs anty-EGFR have decreased level of blood serum magnesium but only few
develop severe hypomagnesemia.

Abstract

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor
(EGFR). Their function is to bind specifically to the extracellular domain of EGFR on both neoplastic
and normal cells which blocks the influence of EGF on the receptor. The important side effect of the
treatment with those drugs, apart from skin toxicity, infusion reactions or nausea, is hypomagnesemia.
Studies show that the mechanism responsible for this effect is the inhibition of EGFR by mAbs in distal
convoluted tubule of the nephron. The EGFR blockage through Ras and mitogen-activated protein kinase
suppress transient receptor potential melastatin submember 6 ion channel responsible for magnesium
reabsorption. The inhibition results in magnesium wasting and secondary hypomagnesemia. Almost all
patients treated with mAbs anty-EGFR have decreased level of blood serum magnesium but only few
develop severe hypomagnesemia.
Get Citation
About this article
Title

The mechanisms of magnesium wasting during the treatment with cetuximab and panitumumab

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 4 (2012)

Article type

Review paper

Pages

143-150

Published online

2012-10-08

Bibliographic record

Onkol. Prak. Klin 2012;8(4):143-150.

Authors

Anna Buda
Mirosława Puskulluoglu

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl